VINC (Vincerx Pharma) Additional Paid-In Capital : $196.08 Mil(As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Additional Paid-In Capital?

Vincerx Pharma's quarterly additional paid-in capital increased from Sep. 2024 ($190.19 Mil) to Dec. 2024 ($191.79 Mil) and increased from Dec. 2024 ($191.79 Mil) to Mar. 2025 ($196.08 Mil).

Vincerx Pharma's annual additional paid-in capital increased from Dec. 2022 ($166.65 Mil) to Dec. 2023 ($170.33 Mil) and increased from Dec. 2023 ($170.33 Mil) to Dec. 2024 ($191.79 Mil).

Vincerx Pharma Additional Paid-In Capital Historical Data

The historical data trend for Vincerx Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Additional Paid-In Capital Chart

Vincerx Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

42.04

156.31

166.65

170.33

191.79

Vincerx Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															170.86	188.77	190.19	191.79	196.08

Vincerx Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Vincerx Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vincerx Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (OTCPK:VINC) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1825 S. Grant Street, San Mateo, CA, USA, 94402

Website

https://www.vincerx.com

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

Executives

Alexander A. Seelenberger	officer: Chief Financial Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi	director, 10 percent owner, officer: Chief Operations Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy	director, 10 percent owner, officer: President and CEO	995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas	officer: See Remarks	180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe	director	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang	officer: Chief Business Officer	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang	officer: Chief Technology Officer	260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens	director	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus	officer: Chief Medical Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd	10 percent owner	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054